A new trading day began on Monday, with Zevra Therapeutics Inc (NASDAQ: ZVRA) stock price up 25.08% from the previous day of trading, before settling in for the closing price of $6.30. ZVRA’s price has ranged from $3.89 to $7.28 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 44.97% over the last five years. Meanwhile, its annual earnings per share averaged -22.31%. With a float of $41.52 million, this company’s outstanding shares have now reached $41.53 million.
The firm has a total of 69 workers. Let’s measure their productivity.
Zevra Therapeutics Inc (ZVRA) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Zevra Therapeutics Inc is 0.79%, while institutional ownership is 33.32%. The most recent insider transaction that took place on Jul 17 ’24, was worth 13,540. In this transaction CFO & Treasurer of this company bought 2,000 shares at a rate of $6.77, taking the stock ownership to the 18,469 shares. Before that another transaction happened on Jul 16 ’24, when Company’s Director bought 10,000 for $6.81, making the entire transaction worth $68,065. This insider now owns 20,000 shares in total.
Zevra Therapeutics Inc (ZVRA) Recent Fiscal highlights
In its latest quarterly report, released on 3/31/2024, the company reported earnings of -0.15 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.42 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -22.31% per share during the next fiscal year.
Zevra Therapeutics Inc (NASDAQ: ZVRA) Trading Performance Indicators
Here are Zevra Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.10. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.35, a number that is poised to hit -0.45 in the next quarter and is forecasted to reach -0.44 in one year’s time.
Technical Analysis of Zevra Therapeutics Inc (ZVRA)
Analysing the last 5-days average volume posted by the [Zevra Therapeutics Inc, ZVRA], we can find that recorded value of 3.15 million was better than the volume posted last year of 0.37 million. As of the previous 9 days, the stock’s Stochastic %D was 59.47%. Additionally, its Average True Range was 0.61.
During the past 100 days, Zevra Therapeutics Inc’s (ZVRA) raw stochastic average was set at 86.79%, which indicates a significant increase from 81.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 127.22% in the past 14 days, which was higher than the 73.30% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.23, while its 200-day Moving Average is $5.29. Now, the first resistance to watch is $8.43. This is followed by the second major resistance level at $8.98. The third major resistance level sits at $9.52. If the price goes on to break the first support level at $7.34, it is likely to go to the next support level at $6.80. Now, if the price goes above the second support level, the third support stands at $6.25.
Zevra Therapeutics Inc (NASDAQ: ZVRA) Key Stats
With a market capitalization of 329.78 million, the company has a total of 41,853K Shares Outstanding. Currently, annual sales are 27,460 K while annual income is -46,050 K. The company’s previous quarter sales were 3,430 K while its latest quarter income was -16,620 K.
